Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Int.J Cancer 9-15-2008;123(6):1227-1239
Industry-leading prior authorization concierge
Given that obesity is a major modifiable risk factor for OSAS, and that the pathogenesis of OSAS involves metabolic dysregulation, systemic inflammation, and abnormal adipose tissue distribution, tirzepatide may offer multidimensional therapeutic benefits in this context (26)
The US obesity rate, after decades of unstoppable growth, has at last started to plateau, but at a level that continues to lead the developed world
US$ 24.77
US$ 23.25
US$ 23.83
US$ 25.21
US$ 29.01
